Radiofrequency ablation as an alternative therapy for renal neoplasms in graft recipients. A preliminary study  by Hernández-Socorro, Carmen Rosa et al.
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etter to the Editor – Brief papers about basic research or clinical experiences
adiofrequency  ablation  as  an alternative  therapy  for renal
eoplasms in graft  recipients.  A preliminary  study
a  ablación  por  radiofrecuencia  como  alternativa  terapéutica  al
ratamiento  de  las  neoplasias  renales  en  pacientes  trasplantados.
n  estudio  preliminarear Editor,
Patients remained in the hospital for 24 h, and a follow-
up abdominal ultrasound was performed before discharge,
to
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Fig. 1 – Ultrasound with contrast of transplanted kidney
after RFA treatment of renal tumour. It shows absencer decades, radical nephrectomy (RN) has been considered
e gold standard treatment for localised renal cell carcinoma.
owever, it has become evident that after RN, a signiﬁcant
umber of solitary kidney patients have an increased risk of
eveloping chronic kidney disease (CKD).1,2 Therefore, in situ
lation methods have been developed; radiofrequency abla-
on (RFA) is being the most used. In transplant patients, renal
mours represent 3% of all neoplasms.3
We  present our preliminary experience of RFA treatment
r small renal tumours (SRT) in transplant patients. The
sults revealed excellent tumour control without deteriora-
on in renal function.
Out of 315 transplant patients being followed-up in our cen-
e, with a median of 16.35 post-transplant years, 5 had renal
mours: 4 in native kidneys and 1 in a transplanted kidney.
nly 1 patient had a radical nephrectomy of a native kidney,
d the others were treated with RFA between September 2013
d December 2014. All lesions were detected by ultrasound,
d were conﬁrmed by with contrast-enhanced ultrasound.
taging was determined by computed tomography (CT) or
agnetic resonance imaging (MRI). The demographic charac-
ristics of the patients and the observed lesions are shown
 Table 1. The comorbidities of the 4 solitary kidney patients
ith CKD were: 3 had dyslipidaemia, 2 had uncontrolled arte-
al hypertension and 1 had severe cardiovascular disease.
Percutaneous RFA was performed in the surgical room
nder general anaesthesia with ultrasound guidance, after
ltrasound-guided ﬁne needle aspiration biopsy of the
mour. Treatment was planned so as to obtain a healthy
ssue ablation margin of 0.5–1 cm width around the tumour
 avoid recurrence, and contrast-enhanced ultrasound study
as performed after completing treatment to assess the
sponse, and if the case of incomplete tumour destruction,
lation was repeated.4
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o conﬁrm the absence of complications. Follow-up was at
month, then every 3 months during the ﬁrst year, and every
months during the subsequent 2 years, which was when
cal recurrence was most common (Fig. 1). Follow-up
cluded contrast-enhanced ultrasound, and CT or MRI  if
quired. Success was deﬁned as the absence of contrast in the
terial phase, indicating complete destruction of the tumour. Santana-Toledo L, Gallego-Samper R, Rodríguez-Pérez JC. La
o de las neoplasias renales en pacientes trasplantados. Un
f enhancement, indicating tumour destruction.
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Table 1 – Demographic characteristic of patients and type of lesions.
PARAMETER VALUE
PACIENTES 
No. of patients 4
Gender
• Male
• Female
4 (100%) 
0 (0%) 
Median age, years 69.5 
Median BMI, kg/m2 26.05 
Median RFA follow-up time ( months) 4.75 
Median elapsed  time since transplantion, years 16.35  
Patient 1
Patient 2 
Patient 3 
PRE-RFA POST-RFA
MDRD
CKD-EPI
41.95 
40.72 
42.9 
41.4 
51.37 
50.26 
47.96 
45.8 
54.41 
52.86 
57.88 
55.21 
) 
) 
Lo
M
Su
M
Su
Ty
Renal function pre/post-RFA (MDRD/CKD-
EPI mL/min)
MDRD
CKD-EPI
RD
-EP
MDRD
CKD-EPIPatient 4 
Immunosuppression
• FK/TAC+MMF+P
• EVE+ MMF+P
3 (75%
1 (25%
TUMOUR CHARACTERISTICS
• Patient  1
• Patient  2
• Patient  3
• Patient 4
Microscopy
• Paciente 1 
• Paciente 2 
• Paciente 3 
• Paciente 4 
MD
CKD46 
42.73 
49 
45.85 
cation Diameter
iddle third 2 cm 
perior pole 1.9 cm 
iddle third 2.1 cm 
perior pole 2.6 cm 
pe I papillary carcinoma
Not done
Renal cell carcinoma
Renal cell carcinoma
I
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The mean duration of the procedure was 60 min  (range,
–70 min). The success rate was 100%. The median follow-
p time was 4.75 months. There were no complications or
complete ablations. Regarding microscopic examination,
e patient with the transplanted kidney tumour had type I
apillary carcinoma. The other patients, with native kidney
mours, had renal cell carcinomas. Only one patient did not
ave a biopsy because radiologically the tumour behaved like a
nal cell carcinoma, and the patient elected to be treated per-
taneously. In the follow-ups completed to date, no patients
ave shown local recurrence or distal metastases. None of
e patients had signiﬁcant changes in renal function pre-
d post-RFA. In our series, the mean creatinine levels of the
patients before RFA and after a mean of 3.2 months of RFA
ere 1.51 and 1.57 mg/dL, respectively.
The diagnosis of renal tumour is increasing in older
atients with comorbidities and renal failure. Treatment
quires techniques that preserve renal parenchyma. Several
thors have described favourable experiences of RFA in SRT,
 terms of both local tumour control and preservation of renal
nction.5–9
Three of our tumours measured less than 3 cm;  one tumour
easured 3.1 cm,  which received 2 sessions of RFA in the same
rgical procedure, for complete tumour ablation.
Tumours adjacent to the great vessels tend undergoes
“heat sink” effect, and conversely the ablative effect on
ophytic tumours is higher, due to the insulating effect of
rrounding perirenal fat that allows higher temperatures.5
 our series, 2 tumours were located in the superior pole and
in the middle third.
The success rate of RFA is 90–100%10; our patients had suc-
ss in all treated tumours without local recurrence.5,8
onclusions
FA offers the advantage of being able to maintain patients’
nal function sufﬁciently to not require a dialysis pro-
amme,  thus avoiding transplantectomy. Transplant patients
ith native kidney tumours do not have to undergo periodic
diological follow-up to assess tumour growth, and are able
 continue their previously established immunosuppressive
eatment.
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